Answers are grounded in this paper and cite their sources.
In Brief Purpose: Vitreomacular adhesion causing vitreomacular traction is a common indication for vitrectomy. It may be avoided by using enzymatic vitreolysis. The MIVI-IIT (traction) study evaluated the ability of a single or repeated injection of microplasmin to release vitreomacular traction. Methods: This randomized, double-masked, Phase II trial with control sham injection enrolled 60 patients. Patients in each of the 4 cohorts were randomized (4:1) to active treatment or sham injection. In the first 3 cohorts, increasing doses of microplasmin (75, 125, and 175 μg) were administered. In the fourth cohort, an initial injection of 125 μg microplasmin or sham was administered followed 1 month later by an injection of 125 μg microplasmin if no release of adhesion occurred. A third dose was injected 4 weeks later if there was still no release of adhesion. Results: Within 28 days of sham, 75, 125, and 175 μg microplasmin administration, nonsurgical resolution of vitreomacular adhesion was observed in 8, 25, 44, and 27% of the patients, respectively. When the 125 μg dose was repeated up to 3 times, adhesion release was observed in 58% of patients 28 days after the final injection. Conclusion: These results provide support for the potential of microplasmin as a nonsurgical treatment for vitreomacular adhesion. Patients with vitreomacular adhesion received a single intravitreal injection (75, 125, or 175 μg) or sham injection or up to 3 repeat intravitreal injections (125 μg) of microplasmin. Resolution of adhesion was found in up to 44% of patients within 1 month after a single injection and in 58% after multiple injections.
No takes yet. Share an insight, caveat, or question.
Stalmans et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: